A Study of Trastuzumab in Combination With TS-ONE and Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Gimeracil/oteracil/tegafur (Primary) ; Trastuzumab (Primary) ; Cisplatin
Indications Gastric cancer
Focus Therapeutic Use

01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
28 Nov 2012 Additional lead trial centre and primary endpoint added as reported by ClinicalTrials.gov. (NCT01736410)
28 Nov 2012 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov. (NCT01736410)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com